Allogeneic Stem Cell Therapy for Acute Ischemic Stroke

医学 改良兰金量表 冲程(发动机) 内科学 安慰剂 临床试验 中风恢复 物理疗法 缺血 缺血性中风 病理 康复 机械工程 替代医学 工程类
作者
Kiyohiro Houkin,Toshiya Osanai,Shinichiro Uchiyama,Kazuo Minematsu,Akihiko Taguchi,Katsuhiko Maruichi,Yoshimasa Niiya,Katsuyuki Asaoka,Yoshihiro Kuga,Katsumi Takizawa,Koichi Haraguchi,Shinichi Yoshimura,Kazumi Kimura,Koji Tokunaga,Atsuo Aoyama,Fusao Ikawa,Chikanori Inenaga,Tatsuya Abé,Atsushi Tominaga,Shinichi Takahashi
出处
期刊:JAMA Neurology [American Medical Association]
被引量:18
标识
DOI:10.1001/jamaneurol.2023.5200
摘要

Importance Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow–derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke. Objective To assess the efficacy and safety of MultiStem when administered within 18 to 36 hours of ischemic stroke onset. Design, Setting, and Participants The Treatment Evaluation of Acute Stroke Using Regenerative Cells (TREASURE) multicenter, double-blind, parallel-group, placebo-controlled phase 2/3 randomized clinical trial was conducted at 44 academic and clinical centers in Japan between November 15, 2017, and March 29, 2022. Inclusion criteria were age 20 years or older, presence of acute ischemic stroke (National Institutes of Health Stroke Scale [NIHSS] score of 8-20 at baseline), confirmed acute infarction involving the cerebral cortex and measuring more than 2 cm on the major axis (determined with diffusion-weighted magnetic resonance imaging), and a modified Rankin Scale (mRS) score of 0 or 1 before stroke onset. Data analysis was performed between May 9 and August 15, 2022. Exposure Patients were randomly assigned to either intravenous MultiStem in 1 single unit of 1.2 billion cells or intravenous placebo within 18 to 36 hours of ischemic stroke onset. Main Outcomes and Measures The primary end points were safety and excellent outcome at day 90, measured as a composite of a modified Rankin Scale (mRS) score of 1 or less, a NIHSS score of 1 or less, and a Barthel index score of 95 or greater. The secondary end points were excellent outcome at day 365, mRS score distribution at days 90 and 365, and mRS score of 0 to 1 and 0 to 2 at day 90. Statistical analysis of efficacy was performed using the Cochran-Mantel-Haenszel test. Results This study included 206 patients (104 received MultiStem and 102 received placebo). Their mean age was 76.5 (range, 35-95) years, and more than half of patients were men (112 [54.4%]). There were no between-group differences in primary and secondary end points. The proportion of excellent outcomes at day 90 did not differ significantly between the MultiStem and placebo groups (12 [11.5%] vs 10 [9.8%], P = .90; adjusted risk difference, 0.5% [95% CI, −7.3% to 8.3%]). The frequency of adverse events was similar between treatment groups. Conclusions and Relevance In this randomized clinical trial, intravenous administration of allogeneic cell therapy within 18 to 36 hours of ischemic stroke onset was safe but did not improve short-term outcomes. Further research is needed to determine whether MultiStem therapy for ischemic stroke has a beneficial effect in patients who meet specific criteria, as indicated by the exploratory analyses in this study. Trial Registration ClinicalTrials.gov Identifier: NCT02961504
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
嘉梦完成签到,获得积分10
1秒前
天天快乐应助Passskd采纳,获得10
1秒前
swy完成签到,获得积分10
1秒前
暴富完成签到,获得积分10
2秒前
kitty完成签到 ,获得积分10
2秒前
5秒前
酷波er应助心好塞采纳,获得10
6秒前
Passskd完成签到,获得积分10
7秒前
fang应助科研通管家采纳,获得10
8秒前
山野村夫应助科研通管家采纳,获得10
8秒前
爆米花应助科研通管家采纳,获得10
8秒前
予修应助科研通管家采纳,获得10
8秒前
liliflower应助科研通管家采纳,获得10
8秒前
伶俐乐菱应助科研通管家采纳,获得10
8秒前
伶俐乐菱应助科研通管家采纳,获得10
8秒前
FAN应助科研通管家采纳,获得10
8秒前
FashionBoy应助科研通管家采纳,获得10
8秒前
天天快乐应助科研通管家采纳,获得10
8秒前
FAN应助科研通管家采纳,获得10
8秒前
8秒前
李治海发布了新的文献求助10
9秒前
zhuzhu完成签到,获得积分10
10秒前
星辰大海应助jiaolulu采纳,获得10
10秒前
11秒前
颖宝老公完成签到,获得积分0
11秒前
清爽夜雪完成签到,获得积分0
12秒前
量子星尘发布了新的文献求助10
12秒前
大翟完成签到,获得积分10
14秒前
不远完成签到,获得积分10
15秒前
冯珂完成签到 ,获得积分10
17秒前
Graham完成签到,获得积分10
17秒前
稳重乌冬面完成签到 ,获得积分10
19秒前
一苇以航完成签到 ,获得积分10
20秒前
戚雅柔完成签到 ,获得积分10
20秒前
vsvsgo完成签到,获得积分10
21秒前
米奇完成签到 ,获得积分10
21秒前
加一点荒谬完成签到,获得积分10
21秒前
21秒前
一一一给轻松白桃的求助进行了留言
23秒前
zz2905完成签到,获得积分10
23秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022